toxylact: a06ab04 phenolphthalein

The first professional lActological database in the word

Drugs in ATC class A06AB04 consist of phenolphthalein, an oral contact laxative that has largely been withdrawn from medicinal use because of carcinogenic risk and limited safety data in breastfeeding.medpedia.framar+2

ATC class and pharmacological profile

Phenolphthalein is classified in ATC group A06AB04, within contact laxatives used for the treatment of constipation. It produces laxative effects by direct irritation of intestinal mucosal receptors, leading to increased colonic peristalsis and facilitated defecation. Historically it was used for symptomatic relief of acute and chronic constipation and for bowel cleansing before procedures, but regulatory authorities have declared it not generally recognized as safe and effective, resulting in withdrawal from many markets.drugbank+4

Toxicological characteristics

Phenolphthalein is an organic triphenylmethane derivative with marked contact irritant properties in the colon. Systemic absorption after oral dosing is limited (around 15%), yet the compound and its metabolites undergo distribution and elimination via bile, urine, feces, and milk. Experimental data have demonstrated carcinogenicity in animals, and it is classified as possibly carcinogenic to humans (Group 2B), which underlies its regulatory restriction as a laxative. Reported adverse effects in humans include nausea, occasional vomiting, abdominal pain, frequent urination, proteinuria, palpitations, hemorrhoidal bleeding, and potential kidney damage with prolonged use.e-lactation+3

In acute exposure, overdose may intensify gastrointestinal irritation and can provoke fluid and electrolyte disturbances; management is supportive, focusing on decontamination and monitoring for shock, pulmonary complications, and seizures in severe cases. Chronic exposure is of particular concern due to the carcinogenic potential and possible nephrotoxicity, so long‑term use is discouraged and safer alternatives from other laxative classes are preferred in clinical practice.chemicalbook+2

Lactation‑related pharmacokinetics and risk assessment

Specific quantitative data on phenolphthalein concentrations in human milk are scarce, and modern lactation pharmacology databases report no recent published measurements of milk levels. Animal data indicate excretion of phenolphthalein and/or its metabolites in milk, confirming that the mammary gland is an elimination pathway. Given its molecular size and lipophilicity, transfer into milk is plausible, although the fraction of maternal dose reaching milk is likely small, in line with general principles of drug excretion into breast milk.ncbi.nlm.nih+3

From a lactological standpoint, the main concerns are: potential gastrointestinal effects (diarrhea, colic) in the breastfed infant due to locally acting drug in the intestinal lumen, and theoretical long‑term carcinogenic risk from repeated low‑dose exposure. Because safer laxatives with much better lactation safety profiles are available, expert sources recommend avoiding phenolphthalein during breastfeeding and prioritizing alternative medications. In situations of inadvertent short‑term maternal use, close clinical observation of the infant for changes in stool pattern, feeding behavior, or unexplained irritability is advisable, but routine breastfeeding cessation is not always necessary after a single low dose.infantrisk+2

Clinical toxicological‑lactological guidance for A06AB04

For healthcare professionals, phenolphthalein in ATC class A06AB04 should generally be considered obsolete as a laxative, particularly in lactating patients. If a product containing phenolphthalein is encountered, risk–benefit evaluation must take into account its carcinogenic classification, adverse‑effect profile, and the lack of robust lactation pharmacokinetic data. In breastfeeding women with constipation, preference should be given to non‑contact laxatives with established safety in lactation (such as osmotic or bulk‑forming agents), following current evidence‑based recommendations from specialized lactation pharmacology resources. Documentation in toxicological‑lactological databases should flag phenolphthalein as a “legacy” contact laxative with probable carcinogenicity and uncertain but potentially harmful exposure for nursing infants, and should clearly direct clinicians toward safer alternatives whenever possible.mdpi+6

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.